Showing 1 - 3 results of 3 for search 'Baek‐Yeol Ryoo', query time: 0.01s Refine Results
  1. 1
    Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan

    Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospec... by Jaekyung Cheon, Shigeo Shimose, Hyung-Don Kim, Takashi Niizeki, Min-Hee Ryu, Tomotake Shirono, Baek-Yeol Ryoo, Hideki Iwamoto, Changhoon Yoo

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Serum 25‐Hydroxyvitamin D Levels and Survival Outcomes in Advanced Biliary Tract Cancer: Results From the NIFTY Trial

    Serum 25‐Hydroxyvitamin D Levels and Survival Outcomes in Advanced Biliary Tract Cancer: Results From the NIFTY Trial by So Heun Lee, Jaekyung Cheon, Ilhwan Kim, Kyu‐pyo Kim, Baek‐Yeol Ryoo, Jae Ho Jeong, Myoung Joo Kang, Byung Woog Kang, Hyewon Ryu, Ji Sung Lee, Changhoon Yoo

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1

    Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1 by Joo Young Jung, Min-Hee Ryu, Baek-Yeol Ryoo, Boram Han, Ji Woong Cho, Man Sup Lim, Hyun Lim, Ho Suk Kang, Min-Jeong Kim, Hong Il Ha, Hunho Song, Jung Han Kim, Hyeong Su Kim, Yoon-Koo Kang, Dae Young Zang

    Published 2016-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: